ATE418346T1 - Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen - Google Patents

Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen

Info

Publication number
ATE418346T1
ATE418346T1 AT05732726T AT05732726T ATE418346T1 AT E418346 T1 ATE418346 T1 AT E418346T1 AT 05732726 T AT05732726 T AT 05732726T AT 05732726 T AT05732726 T AT 05732726T AT E418346 T1 ATE418346 T1 AT E418346T1
Authority
AT
Austria
Prior art keywords
treatment
neuropathic
compositions
neurodegenerative diseases
disclosed
Prior art date
Application number
AT05732726T
Other languages
English (en)
Inventor
J Martin
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Application granted granted Critical
Publication of ATE418346T1 publication Critical patent/ATE418346T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
AT05732726T 2004-04-08 2005-04-07 Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen ATE418346T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56056604P 2004-04-08 2004-04-08
US63145504P 2004-11-29 2004-11-29

Publications (1)

Publication Number Publication Date
ATE418346T1 true ATE418346T1 (de) 2009-01-15

Family

ID=34981912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732726T ATE418346T1 (de) 2004-04-08 2005-04-07 Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen

Country Status (10)

Country Link
US (3) US20050267061A1 (de)
EP (1) EP1732614B1 (de)
JP (1) JP4903689B2 (de)
AT (1) ATE418346T1 (de)
AU (2) AU2005232665B2 (de)
CA (1) CA2561714A1 (de)
DE (1) DE602005011943D1 (de)
ES (1) ES2315859T3 (de)
HK (1) HK1095761A1 (de)
WO (1) WO2005099771A2 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
CA2641198A1 (en) * 2006-02-09 2007-08-16 Sangamo Biosciences, Inc. Method for treating peripheral arterial disease with zinc finger proteins
EP2092068B1 (de) 2006-12-14 2014-10-08 Dow AgroSciences LLC Optimierte nichtkanonische Zinkfingerproteine
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8399218B2 (en) 2007-09-27 2013-03-19 Dow Agrosciences, Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
EP2393506B1 (de) 2009-02-04 2018-03-28 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von nervenleiden
JP5866283B2 (ja) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド トリヌクレオチド反復疾患を治療するための方法および組成物
US8518409B2 (en) * 2010-05-31 2013-08-27 Imperium Biotechnologies, Inc. System for selective cell treatment using ideotypically modulated pharmacoeffectors
US8383405B2 (en) 2010-05-31 2013-02-26 Imperium Biotechnologies, Inc. Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
US9566352B2 (en) 2010-09-27 2017-02-14 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
BR112013008881B1 (pt) 2010-10-12 2021-12-07 The Children's Hospital Of Philadelphia Proteína de ocorrência não natural, nuclease de dedo de zinco, e composição
WO2012094132A1 (en) 2011-01-05 2012-07-12 Sangamo Biosciences, Inc. Methods and compositions for gene correction
RU2459630C1 (ru) * 2011-04-27 2012-08-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) Способ стимулирования нейрогенерации с помощью генетических конструкций
WO2013016446A2 (en) 2011-07-25 2013-01-31 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
IL277027B (en) 2011-09-21 2022-07-01 Sangamo Therapeutics Inc Methods and preparations for regulating transgene expression
CA3099582A1 (en) 2011-10-27 2013-05-02 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
AU2012340213B2 (en) 2011-11-16 2017-12-07 Sangamo Therapeutics, Inc. Modified DNA-binding proteins and uses thereof
CN104204225A (zh) 2012-02-29 2014-12-10 桑格摩生物科学股份有限公司 治疗亨廷顿氏病的方法和组合物
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
DK3196301T3 (en) 2012-07-11 2019-01-14 Sangamo Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING MONOGENIC DISEASES
DK2890780T3 (da) 2012-08-29 2020-09-21 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
RU2665811C2 (ru) 2012-09-07 2018-09-04 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Локусы fad3 для выполнения операций и соответствующие связывающиеся со специфическими сайтами-мишенями белки, способные к вызову направленных разрывов
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
JP2016500254A (ja) 2012-12-05 2016-01-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 代謝疾患の調節のための方法および組成物
AU2014218621B2 (en) 2013-02-25 2019-11-07 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
WO2014144686A1 (en) * 2013-03-15 2014-09-18 University Of Florida Research Foundation Compunds for treating neurodegenerative proteinopathies
EP3057432B1 (de) 2013-10-17 2018-11-21 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen für nukleasevermitteltes genom-engineering in hämotopoietischen stammzellen
AU2014337248B2 (en) 2013-10-17 2020-09-24 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3065540B1 (de) 2013-11-04 2021-12-15 Corteva Agriscience LLC Optimale maispflanzen
EP3066202B1 (de) 2013-11-04 2021-03-03 Dow AgroSciences LLC Optimale sojabohnen-loci
UA120503C2 (uk) 2013-11-04 2019-12-26 Дау Агросайєнсиз Елелсі Спосіб одержання трансгенної клітини рослини кукурудзи
MX362066B (es) 2013-11-04 2019-01-07 Dow Agrosciences Llc Loci óptimos de soya.
EP3068905A4 (de) 2013-11-11 2017-07-05 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur behandlung der huntington-krankheit
DK3492593T3 (da) 2013-11-13 2021-11-08 Childrens Medical Center Nukleasemedieret regulering af genekspression
EP3080143B1 (de) 2013-12-09 2019-02-20 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von hämophilie
PT3102673T (pt) 2014-02-03 2020-05-21 Sangamo Biosciences Inc Métodos e composições para tratamento de beta-talassemia
EP3110454B1 (de) 2014-02-24 2020-11-18 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur nukleasevermittelten gezielten integration
CA2942762C (en) 2014-03-18 2023-10-17 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
FI3169778T3 (fi) 2014-07-14 2023-12-13 Univ Washington State Ituradan soluja ablatoiva nanos-geeninpoisto
CN107075483A (zh) 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 用于过继细胞治疗的工程改造的细胞
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
RU2558294C1 (ru) 2014-09-16 2015-07-27 Общество с ограниченной ответственностью "НекстГен" Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека
EP3878948A1 (de) 2014-09-16 2021-09-15 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen für nukleasevermitteltes genom-engineering und korrektur bei hämotopoietischen stammzellen
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
US20180002379A1 (en) 2015-01-21 2018-01-04 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
EP3277823B1 (de) 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur genomänderung von b-zellen
IL284707B2 (en) 2015-05-12 2024-01-01 Sangamo Therapeutics Inc Regulation of nuclease-mediated gene expression
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2017011519A1 (en) 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP4361279A2 (de) 2015-08-06 2024-05-01 The Curators of the University of Missouri Pathogenresistente tiere mit modifizierten cd163-genen
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
AU2016369490C1 (en) 2015-12-18 2021-12-23 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
AU2017207818B2 (en) 2016-01-15 2024-03-28 Regents Of The University Of Minnesota Methods and compositions for the treatment of neurologic disease
ES2901215T3 (es) 2016-05-27 2022-03-21 Aadigen Llc Péptidos y nanopartículas para la liberación intracelular de moléculas de edición del genoma
JP7033583B2 (ja) 2016-07-13 2022-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド ゲノム編集効率を高めるための方法、組成物及びキット
AU2017315406B2 (en) 2016-08-24 2021-04-01 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
US11896615B2 (en) 2016-10-13 2024-02-13 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
EP3528852A4 (de) 2016-10-20 2020-06-03 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von morbus fabry
EP3532106A4 (de) 2016-10-31 2020-06-24 Sangamo Therapeutics, Inc. Genkorrektur von scid-assoziierten genen bei hämotopoietischen stammzellen und vorläuferzellen
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
CN110249051A (zh) 2016-12-08 2019-09-17 凯斯西储大学 增强功能性髓鞘产生的方法和组合物
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018204469A2 (en) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
KR20200079539A (ko) 2017-11-09 2020-07-03 상가모 테라퓨틱스, 인코포레이티드 시토카인 유도성 sh2-함유 단백질 (cish) 유전자의 유전자 변형
JP2019103139A (ja) * 2017-11-28 2019-06-24 芳樹 前澤 コールセンター業務システム
US20200361877A1 (en) 2018-01-17 2020-11-19 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
MA51619A (fr) 2018-01-17 2021-04-14 Vertex Pharma Inhibiteurs de la protéine kinase dépendante de l'adn
IL276082B2 (en) 2018-01-17 2024-01-01 Vertex Pharma DNA-PK inhibitor compounds, preparations containing them and their uses
KR20200118468A (ko) 2018-02-08 2020-10-15 상가모 테라퓨틱스, 인코포레이티드 조작된 표적 특이적 뉴클레아제
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
KR20210049124A (ko) 2018-08-23 2021-05-04 상가모 테라퓨틱스, 인코포레이티드 조작된 표적 특이적 염기 편집기
WO2020051283A1 (en) 2018-09-05 2020-03-12 The Regents Of The University Of California Generation of heritably gene-edited plants without tissue culture
US20210317430A1 (en) 2018-09-18 2021-10-14 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
CA3125485A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
EP3826664A4 (de) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Verfahren zur behandlung von mukopolysaccharidose typ i
WO2020205838A1 (en) 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia
CN113966401A (zh) 2019-04-10 2022-01-21 犹他大学研究基金会 用于治疗amd的htra1调节
EP4007596A1 (de) 2019-08-01 2022-06-08 Sana Biotechnology, Inc. Dux4+-exprimierende zellen und ihre verwendungen
US20230025289A1 (en) 2019-08-23 2023-01-26 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
WO2021087361A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
WO2021195426A1 (en) 2020-03-25 2021-09-30 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
US20230279440A1 (en) 2020-05-06 2023-09-07 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
EP4146812A1 (de) 2020-05-06 2023-03-15 Cellectis S.A. Verfahren zur gezielten einführung exogener sequenzen in zelluläre genome
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
JP2023537923A (ja) 2020-08-13 2023-09-06 サナ バイオテクノロジー，インコーポレイテッド 感作患者を低免疫原性細胞で処置する方法、ならびに関連する方法及び組成物
EP4204545A2 (de) 2020-08-25 2023-07-05 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
MX2023005665A (es) 2020-11-16 2023-08-01 Pig Improvement Company Uk Ltd Animales resistentes a la influenza a que tienen genes de anp32 editados.
IL303473A (en) 2020-12-31 2023-08-01 Sana Biotechnology Inc Methods and compositions for modulating CAR-T activity
WO2022251367A1 (en) 2021-05-27 2022-12-01 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023287827A2 (en) 2021-07-14 2023-01-19 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
WO2023019203A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) * 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US6001350A (en) * 1987-12-11 1999-12-14 Somatix Therapy Corp Genetic modification of endothelial cells
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US4957773A (en) * 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5503022A (en) * 1993-01-25 1996-04-02 Barone; Larry A. Marine impeller tester
US5797960A (en) * 1993-02-22 1998-08-25 Stevens; John H. Method and apparatus for thoracoscopic intracardiac procedures
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6140466A (en) * 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5585245A (en) * 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
USRE45721E1 (en) * 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5840059A (en) * 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US5944754A (en) * 1995-11-09 1999-08-31 University Of Massachusetts Tissue re-surfacing with hydrogel-cell compositions
WO1997023256A1 (en) * 1995-12-22 1997-07-03 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US6261552B1 (en) * 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5976164A (en) * 1996-09-13 1999-11-02 Eclipse Surgical Technologies, Inc. Method and apparatus for myocardial revascularization and/or biopsy of the heart
CN1195863C (zh) * 1996-10-17 2005-04-06 牛津生物医学（英国）有限公司 逆转录病毒载体
US5931810A (en) * 1996-12-05 1999-08-03 Comedicus Incorporated Method for accessing the pericardial space
US6067988A (en) * 1996-12-26 2000-05-30 Eclipse Surgical Technologies, Inc. Method for creation of drug delivery and/or stimulation pockets in myocardium
US5999678A (en) * 1996-12-27 1999-12-07 Eclipse Surgical Technologies, Inc. Laser delivery means adapted for drug delivery
US5925012A (en) * 1996-12-27 1999-07-20 Eclipse Surgical Technologies, Inc. Laser assisted drug delivery
US20030219409A1 (en) * 1997-01-10 2003-11-27 Biovex Limited Eukaryotic gene expression cassette and uses thereof
US5993443A (en) * 1997-02-03 1999-11-30 Eclipse Surgical Technologies, Inc. Revascularization with heartbeat verification
US6045565A (en) * 1997-11-04 2000-04-04 Scimed Life Systems, Inc. Percutaneous myocardial revascularization growth factor mediums and method
US5893839A (en) * 1997-03-13 1999-04-13 Advanced Research And Technology Institute, Inc. Timed-release localized drug delivery by percutaneous administration
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
US5968010A (en) * 1997-04-30 1999-10-19 Beth Israel Deaconess Medical Center, Inc. Method for transvenously accessing the pericardial space via the right atrium
GB9710809D0 (en) * 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US5863736A (en) * 1997-05-23 1999-01-26 Becton, Dickinson And Company Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples
US6007408A (en) * 1997-08-21 1999-12-28 Micron Technology, Inc. Method and apparatus for endpointing mechanical and chemical-mechanical polishing of substrates
US5972013A (en) * 1997-09-19 1999-10-26 Comedicus Incorporated Direct pericardial access device with deflecting mechanism and method
US6050986A (en) * 1997-12-01 2000-04-18 Scimed Life Systems, Inc. Catheter system for the delivery of a low volume liquid bolus
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US5997509A (en) * 1998-03-06 1999-12-07 Cornell Research Foundation, Inc. Minimally invasive gene therapy delivery device and method
US6066123A (en) * 1998-04-09 2000-05-23 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of bioavailability by use of focused energy delivery to a target tissue
US20040063094A1 (en) * 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
US6048332A (en) * 1998-10-09 2000-04-11 Ave Connaught Dimpled porous infusion balloon
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB9930419D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
AU2695101A (en) * 2000-01-21 2001-07-31 Biovex Ltd Virus strains
GB0001476D0 (en) * 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001255748B2 (en) * 2000-04-28 2006-08-10 Sangamo Therapeutics, Inc. Methods for binding an exogenous molecule to cellular chromatin
AU2884102A (en) * 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7273923B2 (en) * 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
AU2003302752A1 (en) * 2002-12-09 2004-06-30 Toolgen, Inc. Regulatory zinc finger proteins

Also Published As

Publication number Publication date
ES2315859T3 (es) 2009-04-01
US20050267061A1 (en) 2005-12-01
CA2561714A1 (en) 2005-10-27
US20110281937A1 (en) 2011-11-17
AU2005232665A1 (en) 2005-10-27
AU2005232665B2 (en) 2010-05-13
EP1732614A2 (de) 2006-12-20
EP1732614B1 (de) 2008-12-24
AU2010212293A1 (en) 2010-09-02
US20100256221A1 (en) 2010-10-07
HK1095761A1 (en) 2007-05-18
AU2010212293B2 (en) 2012-07-19
JP2007532567A (ja) 2007-11-15
JP4903689B2 (ja) 2012-03-28
WO2005099771A3 (en) 2005-12-08
WO2005099771A2 (en) 2005-10-27
DE602005011943D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
ATE418346T1 (de) Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
ATE548049T1 (de) Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung
DE602005022280D1 (de) Verfahren zur Bekämpfung von Pflanzenkrankheitsschäden durch Verwendung eines Bacillus
DE602004028587D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
EA201270574A1 (ru) Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
UA105046C2 (uk) Пестицидний ген axmi-205 та його використання для захисту рослин від комах-шкідників
SE0701440L (sv) Förfarande för modifiering av polyfenolinnehållande växtmaterial och medicinska användningar av de modifierade polyfenolinnehållande växtmaterialen
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
WO2005112597A3 (en) Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production
SG170819A1 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
DE602005018366D1 (de) Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
WO2006132739A3 (en) Novel chemical compounds
WO2008053478A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2006047728A3 (en) Bmp gene and fusion protein
TW200724679A (en) Treatment of disease using an improved regulated expression system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties